The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.

Item
http://www.wikidata.org/entity/Q35227504
Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatmentA systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysisImpact of Neoadjuvant Chemoradiation on Short-Term Outcomes for Esophageal Squamous Cell Carcinoma Patients: A Meta-analysis.Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program.The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer.Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Significance.HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors?Inter- and intra-observer reproducibility of ADC measurements in esophageal carcinoma primary tumors.Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.
P2860

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.

Item
http://www.wikidata.org/entity/Q35227504
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
type
label
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
prefLabel
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
The biomarker TP53 divides pat ...... es. A p53 Research Group study
@en
P2093
P304
P31
P356
10.1016/J.JTCVS.2014.06.079
P407
P433
P478
P50
P577
P698
P921